Article information
Abstract
Appropriate antimicrobial treatment of shigellosis depends on identifying its changing resistance pattern over time. We evaluated 15,255 stool culture submitted from July 2001 to June 2006 to the Laboratory of Children Medical Center Hospital. Specimen culture, bacterial identification, and disk diffusion susceptibility testing were performed according to National Committee for Clinical Laboratory Standards guidelines. From 15,255 stool samples, 682 (4.5%) were positive for Shigella species. The most common species of Shigella were S. flexneri (48%) and S. sonnei (45%); other results were S. dysenteriae (5%) and S. boydii (2%). The rate of Sensitivity to ceftriaxone (95%), ceftizoxime (94%), and nalidixic acid (84%) were among our isolates. Resistance to co-trimoxazole and ampicillin was 87% and 86%, respectively. S. flexneri was more multiresistant than other species (47.9%). Our isolates are overall most sensitive to ceftriaxone, ceftazidime, and nalidixic acid (> 84%). They were most resistant to co-trimoxazole and ampicillin (> 86%). Because resistance varies according to specific location, continuous local monitoring of resistance patterns is necessary for the appropriate selection of empirical antimicrobial therapy.
Keywords:
Shigella
antimicrobial susceptibility
dysentery
Full text is only aviable in PDF
References
[1.]
C.H. Hoe, R.M. Yasin, Y.T. Koh, K.L. Thong.
Antimicrobial susceptibility and pulsed-field gel electrophoresis of Shigella sonnei strains in Malaysia (1997–2000).
Applied Microbiology J, 99 (2005), pp. 133-140
[2.]
S.H. Ashkenazi, I. Levy, V. Kazaronovski, Z. Samra.
Growing antimicrobial resistance of Shigella isolates.
Antimicrobial Chemotherapy J., 51 (2003), pp. 427-429
[3.]
National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A7. NCCLS, Villanova, PA, USA. 2000.
[4.]
National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS, Wayne, PA, 2000.
[5.]
S.K. Jain, A. Gupta, B. Glanz, J. Dick, G.K. Siberry.
Antimicrobial-Resistant Shigella sonnei: Limited Antimicrobial Treatment Options for Children and Challenges of Interpreting In Vitro Azithromycin Susceptibility.
Pediatr Infect Dis J., 24 (2005), pp. 494-497
[6.]
S. Ashkenazi.
Shigella spp.
Antimicrobial Therapy and Vaccines, pp. 382-387
[7.]
M.S. Green, C. Block, D. Cohen, P. Slater.
Four decades of shigellosis in Israel—the epidemiology of a growing public health problem.
Review of Infectious Diseases, 13 (1991), pp. 248-253
[8.]
H.L. DuPont.
Shigellosis.
Infectious Disease Clinics of North America, 2 (1988), pp. 599-605
[9.]
G.P. Pazhani, T. Ramamrthy, U. Mitra, S.K. Bhattacharya, S.K. Niyogi.
Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhea in Kolkata (Calcutta), India.
Epidemiology and Infection, 133 (2005), pp. 1089-1095
[10.]
A. Khan, S. Huq, M.A. Malek, et al.
Shigella serotypes among hospitalized patients in urban Bangladesh and their antimicrobial resistance.
Epidemiology and Infection, 132 (2004), pp. 773-777
[11.]
Centers for Disease Control and Prevention. NARMS 2001 Annual Report: antimicrobial resistance of Salmonella, Shigella, and E. coli O157 isolates, 2001. Available at: http://www.cdc.gov/narms/annual/2001/table/0104.htm. Accessed June 15, 2004.
[12.]
S. Maraki, A. Georgiladakis, Y. Tselentis, G.A. Samonis.
5 year study of the bacterial pathogens associated with acute diarrhea on the island of Crete, Greece, and their resistance to antibiotics.
Eur J Epidemiol., 18 (2003), pp. 85-90
[13.]
M.L. Replogle, D.W. Fleming, P.R. Cieslak.
Emergence of antimicrobial-resistant shigellosis in Oregon.
Clin Infect Dis., 30 (2000), pp. 515-519
[14.]
E.N. Ozmert, B. Göktürk, K. Yurdakök, S.S. Yalçin, D. Gür.
Shigella Antibiotic Resistance in Central Turkey: Comparison of the Years 1987-1994 and 1995-2002.
Pediatric Gastroenterology and Nutrition J., 40 (2005), pp. 359-362
[15.]
N.S. Shahid, M.M. Rahaman, K. Haider, H. Banu, N. Rahman.
Changing pattern of resistant Shigella bacillus (Shigella dysenteriae type 1) and Shigella flexneri in Bangladesh.
J Infect Dis., 152 (1985), pp. 1114-1119
[16.]
M. Wharton, R.A. Spiegel, J.M. Horan, et al.
A large outbreak of antibiotic-resistant shigellosis at a mass gathering.
J Infect Dis., 162 (1990), pp. 1324-1328
[17.]
M.R. Islam, A.N. Alam, M.S. Hossain, D. Mahalanabis, H.K. Hye.
Double-blind comparison of oral gentamicin and nalidixic acid in the treatment of acute shigellosis in children.
J Trop Pediatr., 40 (1994), pp. 320-325
[18.]
L. Landa.
Cephradine in the treatment of intestinal infections caused by Shigella or Salmonella organisms.
Curr Ther Res Clin Exp., 14 (1972), pp. 496-502
[19.]
W.A. Orenstein, L. Ross, G.D. Overturf, J. Wilkins, D.R. Redfield, A. Underman.
Antibiotic treatment of acute shigellosis: failure of cefamandole compared with trimethoprim/sulfamethoxazole and ampicillin.
Am J Med Sci., 282 (1981), pp. 27-33
[20.]
V.G. Ostrower.
Comparison of cefaclor and ampicillin in the treatment of shigellosis.
Postgrad Med J., 55 (1979), pp. 82-84
[21.]
H.E. Parry.
Oral kanamycin in the treatment of Shigella and Salmonella infections.
Postgrad Med J., (1967), pp. 7-13
[22.]
J.C. Lee, J.Y. Oh, K.S. Kim, et al.
Antimicrobial resistance of Shigella sonnei in Korea during the last two decades.
APMIS, 109 (2001), pp. 228-234
[23.]
Y.S. Jeong, J.C. Lee, H.Y. Kang, et al.
Epidemiology of nalidixic acid resistance and TEM-1- and TEM-52-mediated ampicillin resistance of Shigella sonnei isolates obtained in Korea between 1980 and 2000.
Antimicrob Agents Chemother., 47 (2003), pp. 3719-3723
[24.]
M.L. Bennish, M.A. Salam.
Rethinking options for the treatment of shigellosis.
Journal of Antimicrobial Chemotherapy, 30 (1992), pp. 243-247
[25.]
V. Vasilev, R. Japheth, R. Yishai, N. Andorn.
Antimicrobial resistance of Shigella flexneri serotypes in Israel during a period of three years: 2000-2002.
Epidemiology and Infection, 132 (2004), pp. 1049-1054
[26.]
V. Prado, R. Lagos, J.P. Nataro, et al.
Population-based study of the incidence of Shigella diarrhea and causative serotypes in Santiago, Chile.
Pediatr Infect Dis J., 18 (1999), pp. 500-505
[27.]
J. Ling, K.M. Kam, A.W. Lam, G.L. French.
Susceptibilities of Hong Kong isolates of multiply resistant Shigella spp. to 25 antimicrobial agents, including ampicillin plus sulbactam and new 4-quinolones.
Antimicrob Agents Chemother., 32 (1988), pp. 20-23
[28.]
S. Ashkenazi, M. May-Zahav, J. Sulkes, R. Zilberberg, Z. Samra.
Increasing antimicrobial resistance of Shigella isolates in Israel during the period 1984 to 1992.
Antimicrob Agents Chemother., 39 (1995), pp. 819-823
[29.]
I. Varsano, T. Eidlitz-Marcus, M. Nussinovitch, I. Elian.
Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children.
J Pediatr., 118 (1991), pp. 627-632
[30.]
E. Leibovitz, J. Janco, L. Piglansky, et al.
Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children.
Pediatr Infect Dis J., 19 (2000), pp. 1060-1067
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
